Document Detail


The role of ceramide in major depressive disorder.
MedLine Citation:
PMID:  19876679     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Major depression is a severe mood disorder with a lifetime prevalence of more than 10%. The pharmacokinetic hypothesis claims that a slow accumulation of antidepressant drugs by acid trapping mainly into lysosomes is responsible for the therapeutic latency and that a lysosomal target mediates the antidepressant effects. The lysosomal lipid metabolizing enzyme acid sphingomyelinase (ASM) cleaves sphingomyelin into ceramide and phosphorylcholine. In a pilot study, the activity of this enzyme was increased in peripheral blood cells of patients with major depressive disorder (MDD), making the ASM an interesting molecular target of antidepressant drugs. Indeed, several antidepressant drugs functionally inhibit ASM. The ASM/ceramide pathway might be a missing link unifying independent findings in neurobiology and the treatment of MDD such as therapeutic latency, oxidative stress, immune activation and increased risk of cardiovascular disease.
Authors:
Johannes Kornhuber; Martin Reichel; Philipp Tripal; Teja W Groemer; Andreas W Henkel; Christiane M??hle; Erich Gulbins
Related Documents :
11343609 - Chromium treatment of depression.
6233349 - Concomitant isocarboxazid/mianserin treatment of major depressive disorder.
11532819 - Optimising antidepressant use in clinical practice: towards criteria for antidepressant...
15209599 - Does a depression intervention result in improved outcomes for patients presenting with...
15813939 - Short-term treatment with the antidepressant fluoxetine triggers pyramidal dendritic sp...
12858429 - Pharmacotherapy for chronic depression.
9339609 - Use of lpc antagonist, choline, in the management of bronchial asthma.
12613519 - Echocardiographic evaluation of acute cardiotoxicity in the treatment of hodgkin diseas...
1099859 - Serum lipids during oestradiol-valerate/norgestrel treatment of menopausal women. doubl...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  European archives of psychiatry and clinical neuroscience     Volume:  259 Suppl 2     ISSN:  1433-8491     ISO Abbreviation:  Eur Arch Psychiatry Clin Neurosci     Publication Date:  2009 Nov 
Date Detail:
Created Date:  2009-10-30     Completed Date:  2010-01-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9103030     Medline TA:  Eur Arch Psychiatry Clin Neurosci     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  S199-204     Citation Subset:  IM    
Affiliation:
Department of Psychiatry and Psychotherapy, University of Erlangen, Schwabachanlage 6, 91054 Erlangen, Germany. Johannes.Kornhuber@uk-erlangen.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antidepressive Agents / pharmacokinetics
Brain / metabolism
Ceramides / physiology*
Depressive Disorder, Major / drug therapy,  physiopathology*,  psychology
Double-Blind Method
Humans
Sphingomyelin Phosphodiesterase / drug effects,  metabolism
Chemical
Reg. No./Substance:
0/Antidepressive Agents; 0/Ceramides; EC 3.1.4.12/Sphingomyelin Phosphodiesterase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Repetitive transcranial magnetic stimulation for the treatment of negative symptoms in residual schi...
Next Document:  Prevention of rehospitalization in schizophrenia: results of an integrated care project in Germany.